Financial Performance - Rapid Micro Biosystems reported a quarterly loss of $0.26 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.31 per share a year ago [1] - The company posted revenues of $7.6 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 20.70%, compared to $6.15 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $8.4 million, and for the current fiscal year, it is -$1.06 on revenues of $27 million [7] Stock Performance - Rapid Micro Biosystems shares have increased approximately 46% since the beginning of the year, outperforming the S&P 500's gain of 19.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Rapid Micro Biosystems belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Financial Performance - Total revenue for Q3 2024 reached $7.6 million, a 24% increase from $6.1 million in Q3 2023[3] - Gross margin improved to positive 8%, a 35 percentage point increase compared to negative 27% in Q3 2023[1] - Product revenue rose by 25% to $5.3 million, while service revenue increased by 21% to $2.3 million compared to Q3 2023[3] - Recurring revenue grew by 8% to $3.7 million from $3.4 million in Q3 2023[3] - The company reaffirms its full year 2024 revenue guidance of at least $27.0 million, indicating a growth of at least 20% compared to 2023[7] - Net loss for Q3 2024 was $11.3 million, an improvement from a net loss of $13.4 million in Q3 2023[6] - Total operating expenses were $12.7 million, remaining flat compared to the prior year[5] Growth and Deployment - Seven Growth Direct® systems were placed in Q3 2024, the highest number since Q3 2021[1] - The company is actively engaged with several customers planning global deployments of the Growth Direct system[2] Financial Position - Cash, cash equivalents, and short-term investments totaled approximately $61 million, with no debt outstanding as of September 30, 2024[6]

Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company miles ...

LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company’s management team will host a webcast conference call beginning at ...

Table of Contents ________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ t ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q2 2024 Earnings Conference Call August 2, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Operator Thank you for standing by. My name is Dee and I will be your conference operator today. At this time, I would like to welcome everyone to the Rapid Micro Biosystems Second Quarter 2024 Earnings C ...

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -3.57%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.31, delivering a surprise of -6.90%. Over the last four quarters, the compa ...

Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results • Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 • 150th Growth Direct® system placed with an existing top 15 global pharma customer • First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer • Gross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to ...

Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer Gross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024 Announces operational efficiency program that is expected to en ...

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mis ...